


**Product Name** : M4205  
**Cat. No.** : PC-20159  
**CAS No.** : 2590556-80-0  
**Molecular Formula** : C<sub>29</sub>H<sub>32</sub>N<sub>8</sub>O  
**Molecular Weight** : 508.63  
**Target** : c-Kit  
**Solubility** : 10 mM in DMSO



## Biological Activity

M4205 (IDRX-42) is a potent, highly selective inhibitor of KIT mutations with cell IC<sub>50</sub> of 52 nM on cKIT autophosphorylation in the GIST430/654 cell line.

M4205 inhibits KIT autophosphorylation at Y703 in the imatinib sensitive GIST430 cell line with an IC<sub>50</sub> value of 4 nM.

M4205 inhibits the imatinib-resistant cell line GIST430/654 (exon 11 and exon 13 mutation) and the AML cell line Kasumi-1 (exon 17 mutation N822 K) with IC<sub>50</sub> values of 48 and 4 nM, respectively.

M4205 displays high selectivity in a biochemical panel of 398 kinases at 1 μM, only inhibits PDGFRA, PDGFRB, KIT (wt), FLT3, CSF1R, and lymphocyte-specific protein tyrosine kinase (LCK) with >80% inhibition.

M4205 also displays high cellular kinase selectivity at 1 μM using a panel of NanoBRET assays, only binds to KIT (wt) and FLT3 with 65% and 45% occupancy.

M4205 (35 mg/kg) showed strong in vivo tumor growth inhibition and led to regression in mice bearing GIST430/654 tumor, with dose- and exposure-dependent inhibition of KIT autophosphorylation.

## References

Andreas Blum, et al. J Med Chem. 2023 Feb 23;66(4):2386-2395.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com